Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Feb 15;10(2):e05443.
doi: 10.1002/ccr3.5443. eCollection 2022 Feb.

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib

Affiliations
Case Reports

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib

Shuang Dai et al. Clin Case Rep. .

Abstract

Penile squamous cell carcinoma with pelvic lymph node metastases/recurrence has a poor prognosis. We reported a case with recurrent pSCC was administered cetuximab and anlotinib after failure of first-line treatment and achieved an effective response. Cetuximab combined with anlotinib may be a new choice for relapsed pSCC.

Keywords: chemotherapy; metastases; penial squamous cell carcinoma; recurrence; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The author reports no conflict of interest in this work.

Figures

FIGURE 1
FIGURE 1
(A) Nest of invasive squamous cell carcinoma; (B) Histology of inguinal lymph node metastasis; (C) Finding squamous cell carcinoma in the dermis and subcutaneous fibrous adipose tissue; (D) Histology of the root of the penis metastasis. (A to D): H&E, 20X, respectively)
FIGURE 2
FIGURE 2
Treatment timeline after postoperative recurrence. (A) Left inguinal nodal metastasis; (B) Right inguinal nodal metastasis; (C1) Multiple adjacent tissue and organ metastases; (D1) Tumor progressed rapidly; (C2, D2, E2, F2) Fatty deposition; (E1) The right inguinal soft issue lesion shrank and the edema of right left reduced after two cycles of anlotinib and cetuximab. (F1,F3) Progression after stopping anlotinib and cetuximab
FIGURE 3
FIGURE 3
Edema of right leg. (A) is a pre‐treatment image; (B) is a post‐treatment image

Similar articles

Cited by

References

    1. Djajadiningrat RS, van Werkhoven E, Horenblas S. Prophylactic pelvic lymph node dissection in patients with penile cancer. J Urol. 2015;193:1976‐1980. doi:10.1016/j.juro.2014.12.019 - DOI - PubMed
    1. Pandey D, Mahajan V, Kannan RR. Prognostic factors in node‐positive carcinoma of the penis. J Surg Oncol. 2006;93:133‐138. doi:10.1002/jso.20414 - DOI - PubMed
    1. Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol. 2004;5:240‐247. doi:10.1016/s1470-2045(04)01427-5 - DOI - PubMed
    1. Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009;55:546‐551. doi:10.1016/j.eururo.2008.07.014 - DOI - PubMed
    1. Granados‐García M, Aguilar‐Ponce JL, Maldonado‐Magos F, et al. Advanced squamous cell carcinoma of the head and neck: the current role of cetuximab. ORL J Otorhinolaryngol Relat Spec. 2016;78:320‐333. doi:10.1159/000455891 - DOI - PubMed

Publication types

LinkOut - more resources